Jacobs Levy Equity Management’s Albireo Pharma Inc ALBO Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30,165	Closed	-$652K	–	1100
2022 Q4	$652K	Buy	+30,165	New	+$638K	﹤0.01%	742
2013 Q3	–	Sell	-659	Closed	-$83K	–	1042
2013 Q2	$83K	Buy	+659	New	+$68.6K	﹤0.01%	941

Other funds holding ALBO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jacobs Levy Equity Management's ALBO Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 30,165 shares — an estimated $652K sold.

Jacobs Levy Equity Management first reported a position in ALBO in Q2 2013 and held it in 2 quarters. The position peaked at $652K in Q4 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

Jacobs Levy Equity Management reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 30,165 Albireo Pharma Inc shares in Q1 2023, an estimated $652K.
Jacobs Levy Equity Management first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 2 quarters.
Jacobs Levy Equity Management's Albireo Pharma Inc position peaked at $652K in Q4 2022.
3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.